Validation of Inactivation Methods for Arenaviruses.
arenaviruses
high-risk pathogens
inactivation
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
24 05 2021
24 05 2021
Historique:
received:
31
03
2021
revised:
17
05
2021
accepted:
20
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
19
8
2021
Statut:
epublish
Résumé
Several of the human-pathogenic arenaviruses cause hemorrhagic fever and have to be handled under biosafety level 4 conditions, including Lassa virus. Rapid and safe inactivation of specimens containing these viruses is fundamental to enable downstream processing for diagnostics or research under lower biosafety conditions. We established a protocol to test the efficacy of inactivation methods using the low-pathogenic Morogoro arenavirus as surrogate for the related highly pathogenic viruses. As the validation of chemical inactivation methods in cell culture systems is difficult due to cell toxicity of commonly used chemicals, we employed filter devices to remove the chemical and concentrate the virus after inactivation and before inoculation into cell culture. Viral replication in the cells was monitored over 4 weeks by using indirect immunofluorescence and immunofocus assay. The performance of the protocol was verified using published inactivation methods including chemicals and heat. Ten additional methods to inactivate virus in infected cells or cell culture supernatant were validated and shown to reduce virus titers to undetectable levels. In summary, we provide a robust protocol for the validation of chemical and physical inactivation of arenaviruses in cell culture, which can be readily adapted to different inactivation methods and specimen matrices.
Identifiants
pubmed: 34073735
pii: v13060968
doi: 10.3390/v13060968
pmc: PMC8225210
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Clin Microbiol. 1982 Oct;16(4):704-8
pubmed: 7153317
J Clin Microbiol. 1984 Sep;20(3):486-9
pubmed: 6490832
Antiviral Res. 2004 Sep;63(3):209-15
pubmed: 15451189
Biologicals. 2008 Sep;36(5):330-5
pubmed: 18674928
Emerg Infect Dis. 2009 Dec;15(12):2008-12
pubmed: 19961688
PLoS Negl Trop Dis. 2015 May 21;9(5):e0003793
pubmed: 25996783
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32839250
J Virol Methods. 1994 Mar;46(3):349-52
pubmed: 8006113
Am J Trop Med Hyg. 2019 May;100(5):1275-1277
pubmed: 30860018
Antiviral Res. 2018 Nov;159:63-67
pubmed: 30261226
Viruses. 2018 Mar 13;10(3):
pubmed: 29533988
J Virol Methods. 1985 Jul;11(3):259-64
pubmed: 4030997
Arch Virol. 1989;106(3-4):201-12
pubmed: 2476109
J Virol. 2004 Mar;78(6):3162-9
pubmed: 14990737
Acta Trop. 2003 Aug;87(3):315-20
pubmed: 12875924
Antimicrob Agents Chemother. 1979 Mar;15(3):461-4
pubmed: 464574
PLoS One. 2013 Aug 22;8(8):e72290
pubmed: 23991083
J Virol. 2017 Sep 27;91(20):
pubmed: 28794024
Emerg Infect Dis. 2016 Jul;22(7):1292-4
pubmed: 27070504
J Virol Methods. 2004 Aug;119(2):195-8
pubmed: 15158603
Viruses. 2015 Nov 12;7(11):5875-88
pubmed: 26569291
J Clin Microbiol. 2015 Oct;53(10):3148-54
pubmed: 26179307
Transfusion. 2020 Jun;60(6):1319-1331
pubmed: 32333396
Eur J Clin Microbiol Infect Dis. 2009 Sep;28(9):1155-7
pubmed: 19707804
PLoS One. 2010 Sep 16;5(9):
pubmed: 20862280
Emerg Infect Dis. 2000 Sep-Oct;6(5):466-76
pubmed: 10998376
J Infect Dis. 2017 Oct 17;216(7):859-866
pubmed: 28961947